Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Phase 2 Interventional Results available

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

NCT00315588
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Transplantation
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 21, 2026, 2:36 AM EDT
Completed No phase listed Observational

Development of Predictive Biomarkers

NCT03423862
View directory record Official record
Conditions
Type1diabetes
Interventions
Mixed Meal Tolerance Test
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign

NCT03068273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Real-time CGM data
Device
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 2:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

NCT02239354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
VC-01™ Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 21, 2026, 2:36 AM EDT
Enrolling by invitation Not applicable Interventional

Sleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center

NCT07494188
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 2:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Disaster Preparedness Among Families Caring for Children With Diabetes

NCT00781313
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

NCT01686620
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BIOD-123, Lispro (Humalog)
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Anaheim, California • Chula Vista, California • Concord, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

NCT03443180
View directory record Official record
Conditions
Type1diabetes
Interventions
Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 23 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 21, 2026, 2:36 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multicenter Assessment of the Pancreas in Type 1 Diabetes

NCT03585153
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Non-contrast magnetic resonance imaging
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2050
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

NCT00291356
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
Interventions
GSK189075 oral tablets, GW869682 oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

NCT04721145
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, High Blood Sugar
Interventions
Dexcom G6 Continuous Glucose Monitor
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

NCT04436822
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Escondido, California • Santa Barbara, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 2:36 AM EDT
Completed No phase listed Observational

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

NCT01104142
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 21, 2026, 2:36 AM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

NCT01722266
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 21, 2026, 2:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans

NCT02490124
View directory record Official record
Conditions
Diabetes Type 1
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 21, 2026, 2:36 AM EDT
Completed No phase listed Observational

BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study

NCT02662842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
FlowSmart Infusion Set, Current Infusion Set
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Escondido, California • Atlanta, Georgia • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 21, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

NCT01896869
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ipilimumab, Vaccine, FOLFIRINOX
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 21, 2026, 2:36 AM EDT
Active, not recruiting Not applicable Interventional Results available

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

NCT04336969
View directory record Official record
Conditions
Type1diabetes
Interventions
4T Education and Care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 21 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 2:36 AM EDT